{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:58:56Z","timestamp":1768283936890,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biotechnol Lett"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10529-020-02816-1","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T10:53:53Z","timestamp":1580813633000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8413-5724","authenticated-orcid":false,"given":"Oxana","family":"Selina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilnaz","family":"Imatdinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Balysheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Akasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kryukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Balyshev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Markvicheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"2816_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/0264-410X(91)90285-E","volume":"9","author":"GW Anderson","year":"1991","unstructured":"Anderson GW, Lee JO, Anderson AO, Powell N, Mangiafico JA, Meadors G (1991) Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 9:710\u2013714","journal-title":"Vaccine"},{"key":"2816_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2007.05.023","volume":"343","author":"A Basarkar","year":"2007","unstructured":"Basarkar A, Devineni D, Palaniappan R, Singh J (2007) Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticlesfor controlled delivery of plasmid DNA. Int J Pharm 343:247\u2013254. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.05.023","journal-title":"Int J Pharm"},{"key":"2816_CR3","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1128\/JVI.02641-10","volume":"85","author":"H Boshra","year":"2011","unstructured":"Boshra H, Lorenzo G, Busquets N, Brun A (2011) Rift Valley fever: recent insights into pathogenesis and prevention. J Virol 85:6098\u20136105. https:\/\/doi.org\/10.1128\/JVI.02641-10","journal-title":"J Virol"},{"key":"2816_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-018-0052-x","volume":"3","author":"T Chrun","year":"2018","unstructured":"Chrun T, Lac\u00f4te S, Urien C, Jouneau L, Barc C, Bouguyon E, Contreras V, Ferrier-Rembert A, Peyrefitte CN, Busquets N, Vidal E, Pujols J, Marianneau P, Schwartz-Cornil I (2018) A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting. NPJ Vaccines 3:14. https:\/\/doi.org\/10.1038\/s41541-018-0052-x","journal-title":"NPJ Vaccines"},{"key":"2816_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0167-7799(98)01272-4","volume":"17","author":"JL Cleland","year":"1999","unstructured":"Cleland JL (1999) Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 17:25\u201329. https:\/\/doi.org\/10.1016\/S0167-7799(98)01272-4","journal-title":"Trends Biotechnol"},{"key":"2816_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.4314\/tjpr.v14i10.6","volume":"14","author":"AA Doolaanea","year":"2015","unstructured":"Doolaanea AA, Ismail AFH, Mansor N, Nor NHM, Mohamed F (2015) Effect of surfactants on plasmid DNA stability and release from poly(D, L-lactide-co-glycolide). Trop J Pharm Res 14:1769\u20131778. https:\/\/doi.org\/10.4314\/tjpr.v14i10.6","journal-title":"Trop J Pharm Res"},{"key":"2816_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","volume":"14","author":"B Faburay","year":"2014","unstructured":"Faburay B, Lebedev M, McVey DS, Wilson W, Morozov I, Young A, Richt JA (2014) A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis 14:746\u2013756. https:\/\/doi.org\/10.1089\/vbz.2014.1650","journal-title":"Vector Borne Zoonotic Dis"},{"key":"2816_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/vaccines5030029","volume":"5","author":"B Faburay","year":"2017","unstructured":"Faburay B, LaBeaud AD, McVey DS, Wilson WC, Richt JA (2017) Current status of Rift Valley fever vaccine development. Vaccines 5:29. https:\/\/doi.org\/10.3390\/vaccines5030029","journal-title":"Vaccines"},{"key":"2816_CR10","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3201\/eid1712.111035","volume":"17","author":"AA Grobbelaar","year":"2011","unstructured":"Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R (2011) Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 17:2270\u20132276. https:\/\/doi.org\/10.3201\/eid1712.111035","journal-title":"Emerg Infect Dis"},{"key":"2816_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1128\/CVI.00182-09","volume":"16","author":"DH Holman","year":"2009","unstructured":"Holman DH, Penn Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY (2009) A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol 16:1624\u20131632. https:\/\/doi.org\/10.1128\/CVI.00182-09","journal-title":"Clin Vaccine Immunol"},{"key":"2816_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","volume":"16","author":"T Ikegami","year":"2017","unstructured":"Ikegami T (2017) Rift Valley Fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Vaccines 16:601\u2013611. https:\/\/doi.org\/10.1080\/14760584.2017.1321482","journal-title":"Vaccines"},{"key":"2816_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami T, Makino S (2011) The pathogenesis of Rift Valley fever. Viruses 3:493\u2013519. https:\/\/doi.org\/10.3390\/v3050493","journal-title":"Viruses"},{"key":"2816_CR14","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.1128\/JVI.79.18.12106-12111.2005","volume":"79","author":"T Ikegami","year":"2005","unstructured":"Ikegami T, Won S, Peters CJ, Makino S (2005) Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment. J Virol 79:12106\u201312111. https:\/\/doi.org\/10.1128\/JVI.79.18.12106-12111.2005","journal-title":"J Virol"},{"key":"2816_CR15","unstructured":"Imatdinov I (2014) Construction and cloning of artificial genes encoding immunodominant proteins of Rift Valley fever viruses. Dissertation, Federal Research Center for Virology and Microbiology"},{"key":"2816_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0378-1119(90)90336-P","volume":"96","author":"H Inoue","year":"1990","unstructured":"Inoue H, Nojima H, Okayama H (1990) High efficiency transformation of Escherichia coli with plasmids. Gene 96:23\u201328. https:\/\/doi.org\/10.1016\/0378-1119(90)90336-P","journal-title":"Gene"},{"key":"2816_CR17","first-page":"676","volume":"9","author":"SY Lee","year":"1990","unstructured":"Lee SY, Rasheed S (1990) A simple procedure for maximum yield of high-quality plasmid DNA. Biotechniques 9:676\u2013679","journal-title":"Biotechniques"},{"key":"2816_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","volume":"397","author":"RB Mandell","year":"2010","unstructured":"Mandell RB, Koukuntla R, Mogler LJK, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R (2010) A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397:187\u2013198. https:\/\/doi.org\/10.1016\/j.virol.2009.11.001","journal-title":"Virology"},{"key":"2816_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12917-017-0993-8","volume":"13","author":"C Mroz","year":"2017","unstructured":"Mroz C, Gwida M, El-Ashker M, El-Diasty M, El-Beskawy M, Ziegler U, Eiden M, Groschup MH (2017) Seroprevalence of Rift Valley fever virus in livestock during inter-epidemic period in Egypt, 2014\/15. BMC Vet Res 13:87. https:\/\/doi.org\/10.1186\/s12917-017-0993-8","journal-title":"BMC Vet Res"},{"key":"2816_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-food-022811-101140","volume":"3","author":"CL Onwulata","year":"2012","unstructured":"Onwulata CL (2012) Encapsulation of new active ingredients. Annu Rev Food Sci Technol 3:183\u2013202. https:\/\/doi.org\/10.1146\/annurev-food-022811-101140","journal-title":"Annu Rev Food Sci Technol"},{"key":"2816_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/v8060151","volume":"8","author":"I Phoenix","year":"2016","unstructured":"Phoenix I, Lokugamage N, Nishiyama S, Ikegami T (2016) Mutational analysis of the Rift Valley fever virus glycoprotein precursor proteins for Gn protein expression. Viruses 8:151. https:\/\/doi.org\/10.3390\/v8060151","journal-title":"Viruses"},{"key":"2816_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","volume":"34","author":"PR Pittman","year":"2016","unstructured":"Pittman PR, McClain D, Quinn X, Coonan KM, Mangiafico J, Makuch RS, Morrill J, Peters CJ (2016) Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. Vaccine 34:424\u2013429. https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.030","journal-title":"Vaccine"},{"key":"2816_CR22","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1016\/j.vaccine.2011.02.037","volume":"29","author":"JM Rusnak","year":"2011","unstructured":"Rusnak JM, Gibbs P, Boudreau E, Clizbe DP, Pittman P (2011) Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 29:3222\u20133229. https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.037","journal-title":"Vaccine"},{"key":"2816_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhancedefficacy of DNA vaccines. Expert Rev Vaccines 11:189\u2013209. https:\/\/doi.org\/10.1586\/erv.11.188","journal-title":"Expert Rev Vaccines"},{"key":"2816_CR24","volume-title":"Molecular cloning a laboratory manual","author":"JF Sambrook","year":"2001","unstructured":"Sambrook JF, Russell DW (2001) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, New York"},{"key":"2816_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1134\/S1068162009010130","volume":"35","author":"O Selina","year":"2009","unstructured":"Selina O, Belov S, Vlasova N, Balysheva V, Churin A, Bartkoviak A, Sukhorukov G, Markvicheva E (2009) Biodegradable microcapsules with entrapped DNA for development of new DNA vaccines. Russ J Bioorganic Chem 35:103\u2013110. https:\/\/doi.org\/10.1134\/S1068162009010130","journal-title":"Russ J Bioorganic Chem"},{"key":"2816_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.molliq.2019.03.152","volume":"284","author":"D Trushina","year":"2019","unstructured":"Trushina D, Akasov R, Khovankina A, Borodina T, Bukreeva T, Markvicheva E (2019) Doxorubicin-loaded biodegradable capsules: temperature induced shrinking and study of cytotoxicity in vitro. J Mol Liquids 284:215\u2013224. https:\/\/doi.org\/10.1016\/j.molliq.2019.03.152","journal-title":"J Mol Liquids"},{"key":"2816_CR27","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1021\/bm049669e","volume":"5","author":"D Volodkin","year":"2004","unstructured":"Volodkin D, Larionova N, Sukhorukov G (2004) Protein encapsulation via porous CaCO3 microparticles templating. Biomacromol 5:1962\u20131972. https:\/\/doi.org\/10.1021\/bm049669e","journal-title":"Biomacromol"},{"key":"2816_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.vaccine.2011.11.084","volume":"30","author":"WD Zollinger","year":"2012","unstructured":"Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, Alving CR (2012) Phase I study of a Neisseria meningitides liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine 30:712\u2013721. https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.084","journal-title":"Vaccine"}],"container-title":["Biotechnology Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-020-02816-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10529-020-02816-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-020-02816-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:06:16Z","timestamp":1611446776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10529-020-02816-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2816"],"URL":"https:\/\/doi.org\/10.1007\/s10529-020-02816-1","relation":{},"ISSN":["0141-5492","1573-6776"],"issn-type":[{"value":"0141-5492","type":"print"},{"value":"1573-6776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"23 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}